| Literature DB >> 33177105 |
Sophie Uyoga1, Ifedayo M O Adetifa2,3, Henry K Karanja2, James Nyagwange2, Ambrose Agweyu2, J Anthony G Scott2,3, George M Warimwe2,4, James Tuju2, Perpetual Wanjiku2, Rashid Aman5, Mercy Mwangangi5, Patrick Amoth5, Kadondi Kasera5, Wangari Ng'ang'a6, Charles Rombo7, Christine Yegon7, Khamisi Kithi7, Elizabeth Odhiambo7, Thomas Rotich7, Irene Orgut7, Sammy Kihara7, Mark Otiende2, Christian Bottomley3, Zonia N Mupe2, Eunice W Kagucia2, Katherine E Gallagher2,3, Anthony Etyang2, Shirine Voller2,3, John N Gitonga2, Daisy Mugo2, Charles N Agoti2, Edward Otieno2, Leonard Ndwiga2, Teresa Lambe4, Daniel Wright4, Edwine Barasa2, Benjamin Tsofa2, Philip Bejon2,4, Lynette I Ochola-Oyier2.
Abstract
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Africa is poorly described. The first case of SARS-CoV-2 in Kenya was reported on 12 March 2020, and an overwhelming number of cases and deaths were expected, but by 31 July 2020, there were only 20,636 cases and 341 deaths. However, the extent of SARS-CoV-2 exposure in the community remains unknown. We determined the prevalence of anti-SARS-CoV-2 immunoglobulin G among blood donors in Kenya in April-June 2020. Crude seroprevalence was 5.6% (174 of 3098). Population-weighted, test-performance-adjusted national seroprevalence was 4.3% (95% confidence interval, 2.9 to 5.8%) and was highest in urban counties Mombasa (8.0%), Nairobi (7.3%), and Kisumu (5.5%). SARS-CoV-2 exposure is more extensive than indicated by case-based surveillance, and these results will help guide the pandemic response in Kenya and across Africa.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33177105 PMCID： PMC7877494 DOI： 10.1126/science.abe1916
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728